Evidence map›Paper›PMID 29702494›Full record

ReviewCurrent opinion in ophthalmology2018

Current vaccines for the prevention of herpes zoster.

Allister Gibbons, Anat Galor

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Allister GibbonsUniversity of Miami Miller School of Medicine/ Bascom Palmer Eye Institute.
Anat GalorUniversity of Miami Miller School of Medicine/ Bascom Palmer Eye Institute.
University of Miami · US

Funding

Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Dmitry V Ivanov · 2004 to 2026
$12.2M
Dry Eye and MicroenvironmentR01EY026174 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALOR, ANAT, KUMAR, NARESH · 2016 to 2020
$1.9M
NEI NIH HHS P30 EY014801NEI NIH HHS R01 EY026174
6 · The paper itself

Abstract

purpose of reviewTo summarize the recent advances in the prevention of herpes zoster. The recent Food and Drug Administration (FDA) approval of an adjuvanted subunit vaccine may have a significant impact on the prevention of herpes zoster ophthalmicus. RECENT

findingsThere are currently two commercially available vaccines for the prevention of herpes zoster: a live-attenuated vaccine and a new recombinant subunit vaccine. The latter has been shown to be more effective, have fewer contraindications, but requires two separate inoculations, has higher reactogenicity, and has only short-term postmarketing surveillance. SUMMARY: The adjuvanted zoster subunit vaccine offers several advantages over the previously available vaccine. Following the current treatment recommendations, physicians should recommend vaccination to all patients older than 50 years of age with no contraindications, this should also prevent ophthalmic complications of the disease.

Indexed as

Eye Infections, ViralHerpes Zoster OphthalmicusHerpes Zoster VaccineHumansVaccinationVaccines, AttenuatedHerpes Zoster VaccineVaccines, Attenuated

Identifiers

PMID29702494
PMCPMC13476541
OpenAlexW2799515936

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.